AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 20, 2026, 5:18 PM ET Intellia filed a new shelf registration replacing the one expiring November 24, 2026, covering up to $368,503,261 of common stock remaining under its Jefferies sales agreement. AI-generated summary · Source: SEC filing
Nasdaq Global Market · $NTLAGenetic medicinesRare diseaseRegulatory and execution risk

NTLA Stock Hub: Intellia Therapeutics News, HAE Review and ATTR Safety

Intellia’s first potential product now faces a commercial test as well as a regulatory one. The U.S. Food and Drug Administration (FDA) set March 10, 2027 as its target for acting on lonvoguran ziclumeran, an investigational treatment for hereditary angioedema (HAE). The late-stage transthyretin amyloidosis (ATTR) program has a separate liver-safety history and its own clinical milestones. Intellia finished September with $614.8 million in cash, equivalents and marketable securities as it funded both programs and prepared for a possible launch. Application acceptance · September Form 10-Q.

Last updated: November 18, 2026Financial period: quarter ended September 30, 2026Currency: U.S. dollars
Full research report · PDF
Intellia Therapeutics, Inc. ($NTLA), research updated November 19, 2026
18 pages on the U.S. HAE review, amyloidosis evidence, cash and financing. For personal use only: redistribution prohibited.
Get the report (PDF)
Next scheduled catalyst
December 7, 2026 · Nex-z updates at the CVCT Forum

The Global Cardiovascular Clinical Trialists (CVCT) Forum agenda lists two presentations on nexiguran ziclumeran (nex-z), Intellia’s investigational amyloidosis treatment. One examines cardiac follow-up using an external comparison. The other examines the association between a genetic marker and liver-enzyme elevations. December 7 scientific agenda.

March 10, 2027 is the target action date under the Prescription Drug User Fee Act for the pending hereditary angioedema application. Intellia’s regulatory announcement.

Intellia Therapeutics, Inc. NTLA daily stock chart
Daily chart $NTLA. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

NTLA stock at a glance

Chart analysis · JC
Technical chart analysis of $NTLA with bull and bear scenarios on JC Just Charts.
Cash and marketable securities
$614.8 million
September 30, 2026. Quarterly release.
Nine-month operating cash use
$285.889 million
Nine months ended September 30, 2026. Cash flow statement.
Quarterly net loss
$127.485 million
September quarter. Income statement.
Term loan principal
$75 million
OrbiMed initial tranche, September 4, 2026. Credit announcement.
Basic shares outstanding
140,358,512
October 30, 2026. Cover of Form 10-Q.
Short interest
44,361,762 shares
October 30 settlement. Nasdaq.

Where Intellia stands now

Lonvoguran ziclumeran, or lonvo-z, reached regulatory review with randomized evidence of fewer HAE attacks. Intellia has deployed its field organization ahead of a conditional U.S. launch. A launch would require an approved label, insurer coverage and centers that can deliver treatment and follow patients over time. HAELO study · Commercial preparations and risk factors.

Two separate clinical paths. Nexiguran ziclumeran, or nex-z, is still in Phase 3 development in ATTR. The trial with people who have hereditary polyneuropathy has enrolled its cohort. The cardiomyopathy trial is still advancing enrollment. These Phase 3 studies will test whether the early observations translate into clinical benefit and will add to the evidence on liver safety. November enrollment release · Clinical program update.

Constructive case

Consistent HAE control under a usable label and workable coverage could support demand for one-time treatment. A steady launch would give Intellia more ways to finance amyloidosis development.

Cautious case

Extra review or a slow coverage rollout could leave Intellia carrying launch expenses and two Phase 3 projects longer before product collections arrive. The largest credit tranches have separate conditions.

Latest NTLA news

Nov 20, 2026

Intellia files new shelf registration, keeps $368.5 million at-the-market stock program

Intellia filed a shelf registration statement with the SEC on November 20, 2026 to replace the prior one (File No. 333-275740), which expires on November 24, 2026. It covers common stock, preferred stock, debt securities, warrants and units. A sales agreement prospectus covers up to $368,503,261 of common stock still eligible under the Open Market Sale Agreement with Jefferies LLC. Through November 18, 2026, 28,925,501 shares have been issued under that agreement.

Nov 18, 2026

November amyloidosis poster details long-term nex-z outcomes in hereditary polyneuropathy

The Phase 1 extension followed 31 participants, with median exposure of 3.5 years. The poster reported sustained reductions in transthyretin. Eight participants had at least one serious adverse event. A fatal case of esophageal adenocarcinoma was assessed by the investigator as possibly treatment-related.

Nov 13, 2026

Intellia amends classification of its HAE investor webcast disclosure

The amended Form 8-K identifies the November 12 presentation as an Item 7.01 disclosure. The original exhibit contains the same webcast materials.

Nov 12, 2026

HAE conference materials detail attack rates and use of long-term prophylaxis after lonvo-z

Among 35 HAELO participants assigned to lonvo-z who were using long-term prophylaxis at enrollment, the mean attack rate declined 81 percent compared with their rate on prior prophylaxis. In a separate pooled analysis, all 93 participants were free of long-term prophylaxis at latest follow-up.

Nov 12, 2026

Intellia presents its launch preparations for lonvo-z at HAE investor event

Intellia discussed clinical evidence and U.S. launch preparation for the hereditary angioedema candidate. March 10, 2027 is the pending application’s FDA target action date.

Nov 10, 2026

State Street reports its September 30 Intellia ownership

State Street reported 7,809,060 beneficially owned shares, or 5.6 percent, as of September 30. The organization’s earlier filing reported 6.8 percent as of June 30.

NTLA catalyst calendar

  • September 4, 2026 — Intellia signed the OrbiMed facility and received the initial term loan. Completed financing · Form 8-K
  • September 8, 2026 — Intellia announced acceptance of the lonvo-z application and Priority Review. Company regulatory disclosure · Acceptance announcement
  • November 4, 2026 — Intellia announced that MAGNITUDE-2, its Phase 3 nex-z trial in hereditary polyneuropathy, had completed enrollment. Its November 5 results placed completion in the third quarter. Completed enrollment · Trial announcement · Quarterly update
  • November 5, 2026 — Third-quarter financial results and the September report were filed. Completed filings · Form 10-Q · Results Form 8-K
  • November 6, 2026 — Intellia disclosed restricted stock units granted to three new employees on November 1. Company announcement · Inducement grants
  • November 9, 2026 — Phase 1 cardiac observations, including a subgroup with hereditary polyneuropathy and heart involvement, were presented at the American Heart Association Scientific Sessions. Exploratory analysis · Presentation
  • November 10, 2026 — State Street filed its September 30 beneficial ownership report. Filed disclosure · Schedule 13G
  • November 12, 2026 — Intellia released HAE conference findings and furnished slides for a separate investor webcast. Company data and materials · Meeting release · Form 8-K
  • November 13, 2026 — The amendment corrected the item number of the November 12 webcast filing from 2.02 to 7.01, Regulation FD Disclosure. The slides remained in Exhibit 99.1. Filed amendment · Form 8-K/A
  • November 13–14, 2026 — Five posters and two oral HAE presentations were on the American College of Allergy, Asthma & Immunology agenda. Conference program · Presentation descriptions
  • November 17, 2026 — The Intellia investor webcast at the Jefferies conference in London is listed in the company’s events archive. Past conference · Event and webcast page
  • November 18, 2026 — A long-term Phase 1 poster presented at the International Symposium on Amyloidosis discussed hereditary polyneuropathy. Open-label follow-up · Actual poster
  • December 7, 2026 — The Washington, D.C., cardiovascular trials meeting lists two nex-z presentations on cardiac follow-up and the liver-safety association. Conference agenda · December 7 program
  • March 10, 2027 — Target date for FDA action on lonvo-z in HAE. Regulatory target · Acceptance release
  • First quarter of 2027 — Intellia plans to launch lonvo-z in the United States if the FDA approves the application. Conditional company plan · September-quarter outlook

Evidence behind the two programs

Hereditary angioedema

The pivotal HAE trial measured attacks and the resulting need for rescue care. The first commercial question is how a prospective label and coverage policies translate that benefit into treatment starts. Read the trial analysis.

Transthyretin amyloidosis

Early follow-up reported durable changes in the protein involved in ATTR. Controlled trials are testing cardiovascular events and neuropathy separately. Read the amyloidosis evidence.

Intellia Therapeutics, Inc. deep dive: the full analysis

The chapters follow the HAE candidate from clinical evidence to distribution, then examine amyloidosis safety, operating cash and capital structure. The Merlintrader Research Library collects our dated biotech stock research reports.

01 Three outcomes for the first product and the rest of the portfolio

Intellia’s first product decision will affect how the company funds Phase 3 work that is several milestones behind it. The early commercial signals are likely to be label eligibility, treatment-center participation and how long approved referrals take to reach infusion. Those measures describe different points in a commercial funnel and may improve at different speeds. Sales can lag an increase in referrals while centers and insurers establish payment and follow-up arrangements. Coverage and commercial risks · Investor materials on launch planning.

Bull scenario · Centers turn eligible referrals into treatment

The FDA issues a decision on the intended timetable, and the label covers patients with substantial remaining disease burden or a high burden of recurring preventive therapy. Insurers establish workable criteria, and centers report completed treatment alongside follow-up. An effective rollout would reduce the need to finance both commercialization and clinical development solely from cash already raised. The amyloidosis program would gain a more stable funding base as enrollment and safety work continue.

Base scenario · Approval and access move on different schedules

The regulatory review provides reasonable clarity on the HAE indication. Commercial throughput initially varies with treatment-center readiness and payer policy. Phase 3 amyloidosis spending still competes with launch expenses, and delayed borrowing becomes available in stages as the relevant conditions are met. A few quarters of treatment and collection data would make it possible to distinguish a temporary learning period from a persistently narrow eligible population.

Bear scenario · Costs arrive before a reliable revenue stream

A delay, a tight label or slow payment could leave the company with continued operating cash use and weaker near-term access to the success-based debt tranches. A further liver-safety issue or adverse enrollment development in cardiomyopathy would create a second call on time and cash. The company could respond by reducing spending elsewhere, renegotiating financing or raising equity. Those choices would have different effects on existing common shareholders.

What would falsify this reading

The commercial case weakens if formal coverage decisions repeatedly leave large numbers of otherwise eligible patients unable to proceed. A rise in treatment completions matched by timely collection would strengthen the case more than initial letters of interest, especially if demand comes from several centers and insurer types. The cash report would then show whether the launch is gaining scale quickly enough to support other work.

The amyloidosis case needs interpretable pivotal event or function data. Sustained changes in the biomarker can accompany stable disease, but the clinical relationship depends on organ involvement, severity and follow-up. Additional liver cases or a regulatory enrollment restriction would demand reassessment, particularly if the proposed explanation fails to distinguish lower- and higher-risk groups. Nex-z risks and ongoing studies · Published cardiac cohort.

02 Two medicines at different stages of development

Intellia Therapeutics, Inc. develops investigational genetic medicines for severe diseases. Its two advanced candidates address conditions in which a disease-related protein can be produced in the liver even though symptoms occur elsewhere. The HAE program aims to lower plasma kallikrein activity over time. The amyloidosis program aims to lower circulating transthyretin. The commercial and clinical questions differ because patients, symptoms, available treatments and meaningful endpoints differ. September business overview.

Hereditary angioedema can cause sudden swelling of the extremities, abdominal attacks and dangerous airway involvement. In the forms studied by Intellia, deficient or dysfunctional C1 inhibitor allows excess activity in a pathway that produces bradykinin, increasing vascular permeability. Plasma kallikrein is involved in that pathway. The relevant outcome for patients is how often clinically important attacks occur and what rescue treatment or disruption they cause. A biomarker can support the biological rationale and has limited value by itself as a record of day-to-day disease burden. World Allergy Organization Journal guideline, 2026 · HAELO, New England Journal of Medicine, 2026.

The World Allergy Organization guidance published in 2026 distinguishes on-demand treatment from long-term prevention. An effective preventive plan still needs to account for breakthrough attacks, patient preferences, access and treatment burden. The guidance identifies options including plasma-derived C1 inhibitor, lanadelumab, garadacimab, donidalorsen and berotralstat for preventive care. Each has its own route, interval, eligibility and evidence. That matters for the first launch: Intellia would enter a treated market, where patients may already be well controlled and differ in how much they value avoiding recurring administration. Vázquez et al., World Allergy Organization Journal, 2026.

Transthyretin amyloidosis involves accumulation of misfolded transthyretin in tissues. In the cardiomyopathy form, deterioration may translate into heart-failure events, impaired function and mortality. In hereditary polyneuropathy, weakness, sensory loss and autonomic symptoms can dominate. Some patients have features of both. Disease stability over time after treatment has to be judged against the patient’s initial burden and appropriate comparator data. A program with one molecular target can therefore require different trials and regulatory evidence for the two populations. Fontana et al., NEJM, 2024 · Gillmore et al., NEJM, 2025.

Intellia is the lead developer for both late-stage candidates. Under the amyloidosis collaboration, Regeneron Pharmaceuticals, Inc. bears approximately 25 percent of worldwide program development costs, shares in approximately 25 percent of commercial profits, and has an option to participate in U.S. promotion. The quarterly collaboration revenue is substantially related to that agreement. Company spending on the HAE launch and the timing of any direct HAE receipts follow a different set of economics. Note 7 and management discussion.

03 What the conference and regulatory dates can resolve

The September 8 acceptance announcement puts the HAE application on a Priority Review schedule. March 10 is the target action date under the Prescription Drug User Fee Act. Intellia said the agency was not then planning an advisory committee. The decision will establish whether the candidate receives marketing authorization and, if so, the initial label and any applicable obligations. An investor timetable that assumes a specific indication, safety language or launch day before that decision can miss important differences between approval and commercial usability. September application and review announcement.

The November investor materials and medical-meeting disclosure serve different purposes. On November 12 Intellia published new conference observations covering durability, attack burden and patients’ experiences. Separately, the company furnished slides for its HAE investor webcast. A November 13 amendment corrected the item number of the webcast filing (see the catalyst calendar). Meeting disclosures · Original presentation exhibit · Amended Form 8-K.

The company’s investor-relations archive has an event and webcast page for the November 17 Jefferies conference. On November 18 the long-term clinical poster at the International Symposium on Amyloidosis provided a different type of evidence: follow-up of a defined subset from an open-label trial. The poster reports patient follow-up through June 29, 2026. Jefferies event and webcast · International Symposium poster.

The December 7 cardiovascular forum can add detail on the cardiac cohort’s safety and clinical course and on the association with liver-enzyme elevations. The announced cardiac comparison uses patients at the National Amyloidosis Centre as an external group. Even if matching makes the groups similar on measured factors, the treatment assignment remains observational. The randomization in Phase 3 will address a stronger comparative question. The conference is most useful for judging where residual safety uncertainty remains and what needs to be tested prospectively. December 7 agenda · MAGNITUDE study record.

04 What HAELO establishes and what follow-up adds

Cohn and colleagues reported the randomized HAELO trial in the New England Journal of Medicine in 2026. It included 80 participants aged 16 or older with HAE due to C1-inhibitor deficiency, with 52 assigned to lonvo-z and 28 to placebo. The primary comparison counted investigator-confirmed attacks from weeks 5 through 28. Adjusted monthly attack rates were 0.26 with lonvo-z and 2.10 with placebo, a relative reduction of 87 percent, with a 95 percent confidence interval corresponding to a reduction of 78 to 93 percent. This endpoint measures attack frequency during the defined observation window. Cohn et al., NEJM, 2026 · Trial registry.

The average monthly result and a patient’s experience of having no attacks are different measures. Intellia reported that 62 percent of the active-treatment group and 11 percent of the placebo group had no HAE attacks and used no additional HAE therapy during the efficacy period. Attacks requiring on-demand treatment averaged 0.19 per month versus 1.79, and moderate or severe attacks averaged 0.11 versus 1.23. The Angioedema Quality of Life score improved by 23.51 points versus 6.47 at week 28, expressed as a decrease in scores. Taken together, those measures cover clinical events, the burden of acute intervention and the patient’s experience. They derive from the same randomized trial. The attack outcomes cover weeks 5 through 28, while the quality-of-life score measures change from baseline to week 28. Form 10-Q, HAELO secondary endpoints · Published HAELO study.

Through week 28, treatment-emergent adverse events were reported in 92 percent of lonvo-z participants and 86 percent of placebo participants. Frequently reported events that occurred more often in the lonvo-z group included infusion-related reactions, headache and fatigue. The study reported no serious or grade 3 or higher adverse events in the lonvo-z group during the reported period. The median follow-up at the February 10 cutoff was 7.5 months. Because uncommon events can be missed in a group of 52 and delayed events accrue over more time, the absence of a severe event in this interval is an observation about that cohort and period. Randomized safety data and follow-up.

The November 12 meeting release reported an 81 percent reduction in attack rates among 35 HAELO patients assigned to lonvo-z who were using long-term prophylaxis at study entry. That analysis compares the same patients’ post-treatment experience with their experience on prior therapy. It differs from a randomized comparison that assigns patients to lonvo-z or a current preventive drug. The same release describes interviews with 23 Phase 1/2 patients, all of whom described their disease as well controlled and 22 of whom described lonvo-z as an optimal therapy. Those interviews give examples of what participants value and have a selected sample. Company report of the November meeting analyses.

Across 93 participants who received a single 50 mg dose of lonvo-z in the Phase 1/2 and Phase 3 studies, the company reported an 89 percent decrease in the rate of attacks from baseline through up to four years of follow-up, which differed by participant. Individual study periods and crossover matter when interpreting the pooled figure. In HAELO, placebo participants were eligible to cross to active treatment after week 28, which makes longer-term data informative about durability and less suitable for maintaining the original randomized contrast. The questions after approval would include recurrence, later use of rescue or preventive therapy and retention in long-term registries. November analysis and cutoffs · Trial crossover and outcome definitions.

Existing prevention has its own controlled evidence. In the HELP study, Banerji and colleagues reported in JAMA in 2018 that 125 randomized participants had mean monthly attack rates ranging from 0.26 to 0.53 on the studied lanadelumab regimens versus 1.97 with placebo over 26 weeks. The HAELO and HELP studies differed in who participated, how observation was organized and how the therapies were used. Clinical decisions about switching also depend on a patient’s prior control and tolerance for uncertainty in long-term follow-up. A direct comparison or appropriately designed real-world evidence would answer a different question from two separate placebo comparisons. Banerji et al., JAMA, 2018 · Cohn et al., NEJM, 2026.

05 The operating work between approval and a first sale

On November 5, Intellia said it had deployed its field team and was working with treatment centers and insurers. It was planning a U.S. launch in the first quarter of 2027 subject to approval. That preparation advances the point at which the company can act after a favorable decision. It also brings operating expenses forward. The annual commercial result will depend on how the eventual label intersects with referral criteria, payer documentation and the ability of specialists to arrange treatment and monitoring. November 5 readiness update · Commercialization risks.

A one-time option changes the unit of commercial activity. Recurring preventive products can generate continuing demand from existing users. For a one-time therapy, continued demand depends on bringing new eligible patients through referral and treatment. A backlog of patients waiting for review could produce a different early pattern from long-run uptake. Patients who receive the treatment would still need medical follow-up, and the company identifies reimbursement for follow-up as a separate uncertainty. Commercial volume should be interpreted alongside how many centers are actually treating, whether referrals convert and how quickly cash is collected. Coverage, reimbursement and commercial risks · Investor launch materials.

The company says U.S. payers have no uniform coverage or reimbursement policy. A treatment-center agreement can be in place while individual insurers consider medical necessity, care setting or reimbursement. Some patients may be satisfied with long-term prevention, while patients with difficult control or a burdensome care regimen may have stronger reasons to explore a one-time treatment if the label permits it. Neither the number of physicians contacted nor trial enthusiasm is a direct measure of reimbursed treatment. A launch may first reveal differences among insurers, centers and regions before it provides a clear long-term demand signal. Risks related to patient and payer acceptance · Guidance on individualized prevention.

Manufacturing supply and dependable release of batches also matter before accounting revenue can follow patient interest. Intellia relies in part on outside organizations for clinical and manufacturing work and discusses the cost and time required to replace vendors. Commercial reliability would include recurring delivery and follow-up across settings without depending on a single clinical-trial site’s infrastructure. The costs of running that system will affect how much any new revenue can fund the ATTR studies. Manufacturing, suppliers and commercialization risks.

06 What the amyloidosis trials are testing

The Phase 3 MAGNITUDE trial concerns patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Its design targets about 1,200 adults and a primary composite of cardiovascular death and cardiovascular events. Events are the clinically meaningful test because circulating transthyretin is upstream of the accumulated disease. The September report and the November update describe continuing enrollment in the cardiac trial. The registry estimates primary completion in December 2027. MAGNITUDE in Form 10-Q · MAGNITUDE trial record.

MAGNITUDE-2 concerns hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). Intellia announced completed recruitment on November 4. In its November 5 update it said recruitment finished during the September quarter and exceeded its target of 60 randomized participants. The registry lists actual enrollment of 67. The study pairs a change in a validated neuropathy impairment score at month 18 with a serum transthyretin measure at day 29. These two endpoints answer clinical and biological questions at different times. Month 18 is measured relative to an individual patient’s baseline. The trial registry estimates primary completion in July 2027, and the November announcement gave no aggregate readout date. November 4 enrollment announcement · November 5 quarterly update · MAGNITUDE-2 study record.

In the published early cardiomyopathy study, Fontana and colleagues followed 36 treated participants for at least 12 months. Mean serum transthyretin was down 90 percent at 12 months. For the six-minute walk, the median change was 5 meters, and the middle half of observations ranged from a 33-meter decrease to a 49-meter increase. Five patients had transient infusion-related reactions and two had transient liver enzyme elevations assessed as related to treatment. The open-label group provides useful time-series observations and the range makes clear how much individual function can vary. Fontana et al., NEJM, 2024.

Gillmore and colleagues reported results from 36 patients with hereditary polyneuropathy in the New England Journal of Medicine in 2025. Mean follow-up was 27 months. Among the reported observations, the 24-month average change in the modified Neuropathy Impairment Score +7 was −8.5 points, where a lower score indicates less measured impairment. There was one death from cardiac amyloidosis and one withdrawal after progressive motor decline. The estimates come from an open-label study that includes observations at different follow-up times. A larger controlled comparison in MAGNITUDE-2 will provide more evidence on whether clinical function is preserved. Gillmore et al., NEJM, 2025 · Pivotal endpoint definitions.

Vutrisiran provides a useful example of the controlled evidence already available to clinicians. In the January 2025 issue of the New England Journal of Medicine, Fontana and colleagues reported HELIOS-B, which randomized 655 ATTR-CM patients. The hazard ratio for death from any cause and recurrent cardiovascular events was 0.72 for vutrisiran versus placebo, with a 95 percent confidence interval of 0.56 to 0.93. MAGNITUDE uses its own cardiovascular endpoint, eligibility rules and follow-up. A large reduction in a shared biomarker in a separate early study cannot establish how an intervention compares with the clinical outcome results of HELIOS-B. Fontana et al., NEJM, 2025 · MAGNITUDE registry.

The November 9 American Heart Association poster compared cardiac observations across a cardiomyopathy group and a selected mixed-phenotype subgroup from Phase 1. Its post hoc subgroup definition is relevant when interpreting apparent stability or improvement in cardiac measures. Individuals with mixed polyneuropathy and cardiac involvement had different starting profiles from those enrolled for cardiomyopathy. The analysis helps describe the range of responses across presentations of ATTR and leaves the event-reduction question to the larger randomized study. November 9 American Heart Association presentation.

07 Liver safety and the long-term polyneuropathy poster

The FDA placed both Phase 3 programs on hold on October 29, 2025, after a MAGNITUDE participant developed grade 4 liver transaminase elevations and increased total bilirubin. The participant died on November 5, 2025. According to the clinical investigator as reported in the 10-Q, the cause was septic shock secondary to a perforated duodenal ulcer. Acute liver injury and its treatment with corticosteroids were part of the clinical course. The company said the autopsy supported the clinical diagnoses. These distinctions matter because the severe hepatic event prompted the pause, while the reported medical cause of death was a separate part of the sequence. September Form 10-Q, clinical hold and clinical course.

The hold on MAGNITUDE-2, the neuropathy study, was lifted in January 2026. The company announced the lifting of the hold on the cardiac study on March 2. A study resuming gives investigators an opportunity to characterize both benefit and harm in additional participants. In August, Intellia reported that a genomic analysis across more than 600 patient samples found the largest liver enzyme elevations among carriers of a specific human leukocyte antigen (HLA) variant. The company said it was discussing the finding with regulators and would share genotyping results with investigators and patients enrolled in or entering screening for the two studies. In November it reported that it had begun sharing results with investigators during the third quarter. Until the association can be tested prospectively, it remains uncertain how well the finding predicts who will experience a severe event. January hold release filing · March hold release announcement · FDA hold chronology and biomarker analysis · August communication on the plan · November progress disclosure.

The November 18 poster described a different group: selected participants from the open-label Phase 1 ATTRv-PN cohort. Thirty-three had received the treatment in the reported analysis subset, 31 entered long-term follow-up, and the median exposure duration was 3.5 years as of June 29, 2026. The poster reported mean transthyretin reductions of 92.5 percent at 36 months and 93.1 percent at 48 months, with smaller observed samples at later time points. Measuring the protein across those visits is evidence of sustained biological activity. The numbers of observations and the absence of a concurrent placebo group limit conclusions about later clinical outcomes. November 18 poster, follow-up and Figure 3.

In the group of 31 in long-term follow-up, eight had a serious adverse event. The poster reports one fatal case of esophageal adenocarcinoma that the investigator considered possibly treatment-related, in a participant with preexisting risk factors. The reported follow-up table contained no serious liver event. This case and the patient death in MAGNITUDE in 2025 involve different participants, cohorts and clinical histories. A small extension that records selected adverse events supplies important observations but cannot establish their population frequency or rule out late risks. November 18 poster, Table 2 and footnotes · MAGNITUDE clinical history.

08 The September accounts show the cost of preparing a launch

All revenue in the September quarter came from collaborations. The income statement records costs for both late-stage development and a commercial organization being built ahead of potential product revenue. The expense mix is more informative than the headline loss alone. A decline in research and development expense coincided with higher general and administrative spending, and investment remeasurement pulled the quarterly bottom line down further. Income statement and management discussion.

U.S. dollars and shares in thousands, except per-share amountsQ3 2026Q3 20259M 20269M 2025
Collaboration revenue7,16313,78229,87044,654
Research and development83,34694,747246,678300,209
General and administrative46,14230,512118,80986,725
Total operating expenses129,488125,259365,487386,934
Operating loss(122,325)(111,477)(335,617)(342,280)
Interest income and other, net5,8376,71416,83922,719
Interest expense(611)—(611)—
Change in fair value of investments, net(10,386)3,439(10,961)2,653
Net loss(127,485)(101,324)(330,350)(316,908)
Basic and diluted loss per share(0.91)(0.92)(2.53)(2.99)
Weighted-average shares, in thousands140,186110,188130,802105,841

The quarterly operating loss increased even though the nine-month operating deficit improved against the comparable 2025 period. Lower year-to-date research spending more than offset higher administrative expense and lower collaboration revenue. Intellia attributes the quarterly administrative increase in part to commercial infrastructure, legal costs and personnel. In research, external spending by program was $21.449 million for nex-z and $10.216 million for lonvo-z in Q3, compared with $19.944 million and $15.069 million respectively a year earlier. Other research and development cost $51.681 million. Some employee, facility and research costs serve multiple programs, so direct program figures measure a subset of research expense. Segment note and research expense tables.

Intellia booked $6.8 million of quarterly revenue from Regeneron’s share of ATTR collaboration costs, compared with $8.4 million a year earlier. Regeneron exercised its one-time option in October 2023, extending the older technology collaboration through April 2026. Intellia recognized no revenue under the 2016 agreement in the third quarter. It had recognized $5.3 million under it a year earlier. At September 30, accounts receivable from the Regeneron arrangements were about $7.5 million and their deferred revenue balance was zero. These cost-sharing and licensing revenues help fund the development program. Commercial receipts would come from a separate line of activity after an approved launch. Note 7, collaboration revenue and balances.

AvenCell Therapeutics, Inc., Kyverna Therapeutics, Inc. and ONK Therapeutics, Ltd. have agreements with Intellia. Revenue from those arrangements was immaterial in the period. The company also reports a $7.982 million equity investment in Kyverna at September 30, classified under investments and other assets. Holdings in another biotechnology company can change in accounting value without producing corresponding cash inflows, which is one reason to reconcile the income statement and cash flows separately. Notes 7 and 8.

09 Cash consumption and the assumptions behind runway

At September 30, the balance sheet shows $156.098 million in cash and equivalents, $318.012 million in current marketable securities and $140.697 million in noncurrent marketable securities. Merlintrader calculation based on the three reported lines: $614.807 million. The results release rounds this to $614.8 million. Restricted cash equivalents of $15.404 million are included in other assets and are outside that combined total. The funded term loan, whose net carrying amount was $73.731 million, is also reflected as a liability. Available corporate resources and contractual claims on them both matter for planning. Balance sheet and cash reconciliation · Results release.

Operating cash use was $285.889 million during the first nine months, versus $325.451 million a year earlier. The June and September filings give two cumulative reports. Merlintrader calculation: subtracting first-half use of $200.459 million from nine-month use gives $85.430 million of third-quarter use. By the same subtraction, the 2025 third quarter used $76.899 million. A smaller cash deficit over the first nine months can therefore coexist with a higher deficit in the latest quarter. The contrast is material when assessing how much launch preparation will cost ahead of receipts. September cash flows · June cash flows.

The September cash flow statement reports $2.776 million spent on property and equipment in the nine months. Net investing cash use of $13.319 million includes purchases, maturities and sales of marketable securities. Net financing proceeds of $303.142 million include the equity raise, earlier at-the-market issuance and the term loan. Buying a marketable security reduces cash and increases securities, whereas an operating outlay consumes a resource without that offset. These flows explain how the combined cash and securities balance could be near its year-end level while operating cash outflow remained substantial. Cash flow statement and management discussion.

Management expects September liquidity and collaboration funding to cover operating expenses and capital expenditures at least into 2028 under its current assumptions. The guidance includes the April equity raise and initial September lending proceeds already in the balance. It excludes potential commercial revenue from lonvo-z, potential collaboration milestones and extension fees, and strategic spending outside the base case. The November results release also excludes further draws of the term loan from the runway statement. The guide is useful as a financing plan, while actual burn depends on how fast the commercial team, trials and related infrastructure scale. Capital resources outlook · November 5 liquidity guidance.

The operating lease note shows total lease liabilities of $156.413 million and gross future operating lease payments of $270.753 million at quarter-end. The stated schedule excludes $33.9 million for a Tech Square floor whose lease component had yet to commence under the accounting rules. Gross lease payments extend beyond the immediate launch period. Looking at annual lease payment dates alongside cash used by operations gives a better view of near-term needs than deducting the full undiscounted commitment from cash as though it were immediately due. Note 9, lease payment schedule.

10 OrbiMed funds a first tranche with further amounts tied to milestones

On September 4 Intellia closed a five-year senior secured credit agreement with OrbiMed for up to $400 million. The initial $75 million draw is the principal already borrowed. Beyond it, the agreement includes an optional $75 million tranche if the FDA approves lonvo-z by the specified time, three optional $40 million tranches tied to product revenue milestones and an optional $30 million tranche tied to an equity fundraising milestone. Another $100 million is uncommitted and would require agreement with the lenders. Financing capacity can therefore expand if the clinical, regulatory and commercial plans advance. An approval delay could affect access to capital at the point when launch spending is already underway. September 4 financing Form 8-K · Note 10, loan terms.

Principal on the initial and delayed-draw term loans is due on September 4, 2031. The parties would set the maturity for any separate incremental loan. Interest is payable monthly at an annual rate of 6.15 percentage points plus the greater of 3.00 percent and the one-month Term Secured Overnight Financing Rate (Term SOFR). The initial loan’s effective accounting rate at September 30 was 11.1 percent. That rate incorporates different items from the base rate formula. The delayed draws carry an annual 0.50 percent fee on undrawn amounts until the relevant commitments terminate or are funded, no later than March 31, 2029. Those commitment costs can precede funding of a later tranche. Interest rates, fees and timing.

The credit agreement provides for repayment premiums from zero to 3 percent and exit fees ranging from 3.75 to 4.75 percent, depending on timing. An early repayment before the 13-month anniversary of the relevant loan closing can incur an additional payment tied to scheduled interest through that point. These amounts affect the economics of replacing the facility, even if a different lender offers a lower nominal rate. The carrying amount in the balance sheet reflects specified fees and debt issuance costs. Contractual principal and cash required at repayment are tracked separately. Debt balance and prepayment terms.

The facility has a first-priority security interest, subject to exceptions, over substantially all Intellia assets including intellectual property. The agreement requires at least $50 million in U.S. controlled accounts until traditional FDA marketing approval of lonvo-z in hereditary angioedema. Accelerated approval alone would leave that requirement in place. The product revenue covenant includes exceptions for satisfying a contractual equity-value threshold or maintaining qualifying liquidity at least equal to outstanding loan principal in U.S. controlled accounts throughout the quarter. Consequently, available spending can depend on how much of the reported liquidity must stay in controlled accounts. The funding agreement also restricts certain additional debts, asset sales and licensing transactions. Collateral and financial covenants · Credit agreement, Section 8.4.

11 Issued shares and contractual dilution

Intellia reported 140,358,512 common shares outstanding on October 30. The September balance sheet count was 140,253,812, versus 116,317,060 at December 31, 2025. The latest share count and the quarterly weighted-average denominator represent different concepts. The former is a snapshot at a specified date and the latter is used to calculate period earnings per share. This difference matters when an offering occurs during the year, as it did in April. Cover, balance sheet and earnings per share.

The April offering closed with $194.580 million of net proceeds in the cash flow statement. The agreement initially covered 16,744,187 shares, and the underwriters exercised an option on a further 2,511,628 shares. The statement of equity reports 19,255,815 shares issued in the deal. Separately, 2,612,344 shares sold under the at-the-market program generated $33.569 million net in the nine months. At September 30 the company reported $368.5 million of remaining eligibility under the program. That amount measures authorization and is separate from executed sales. Note 13, cash flows and changes in equity.

At September 30 Intellia had 5,700,490 outstanding options and 6,298,156 unvested restricted stock units (RSUs). Of those options, 4,444,287 were exercisable. The weighted-average exercise price of all outstanding options was $36.57, a contractual figure. The earnings-per-share note excludes the option and unit categories from diluted loss per share because their inclusion in a loss period would be antidilutive. The table lists only those categories of excluded share equivalents at quarter-end. Future vesting, exercises and financing may still increase the share count. Stock-based compensation and per-share notes.

Intellia subsequently disclosed compensation awards that sit outside the September share counts. Jing L. Marantz, the chief medical officer, reported restricted stock units on 199,822 shares and options on 275,061 shares with a contractual exercise price of $11.26. The October Form 4 uses transaction code A for awards. On November 6 the company said it had granted three new employees restricted stock units on 12,900 shares on November 1, with vesting over three years subject to continued service. Tracking these categories separately preserves the distinction between awards that vest over time, an executive’s open-market transactions and newly issued common shares. Marantz’s October Form 4 · November inducement disclosure.

12 Beneficial ownership, insider transactions and liquidity

State Street Corporation’s November 10 Schedule 13G reported 7,809,060 shares, or 5.6 percent, at September 30. Its earlier Schedule 13G, filed August 7, reported 9,234,987 shares and 6.8 percent at June 30. Both figures exceed five percent. The filings describe beneficial ownership at two dates. The comparison measures the change in reported interest between those dates. ARK Investment Management LLC reported 14,207,324 shares, or 12.27 percent, at December 31, 2025, in its February 3 amendment. That is a year-end snapshot, measured when 116,317,060 shares were outstanding. ARK has filed no later amendment as of November 19, 2026, and the share count has since risen to 140,358,512 (October 30), so the 12.27 percent is not a current stake. State Street November filing · State Street August filing · ARK February amendment.

The Vanguard Group parent exited the five-percent reporting category. Its March 27 amendment reported zero shares and zero percent as of March 13 after an internal realignment put certain units on separate reporting. Initial Schedule 13G filings by Vanguard Portfolio Management (April 29) and Vanguard Capital Management (April 30) recorded 6,266,007 shares (5.30 percent) and 5,945,571 shares (5.03 percent) respectively at March 31. Each disclosure identifies a reporting entity and event date. The realignment explains why a parent-level report dropped to zero while separate units made their own initial reports. Both unit figures are March 31 snapshots: neither unit has filed again as of November 19, 2026, and the share count has since risen to 140,358,512, so neither percentage is a current stake. Two other institutions reported holdings below five percent at December 31, 2025, which are exits from the reporting threshold: Contrarius Investment Management (0.6 percent, amendment of February 11) and The Goldman Sachs Group (2.7 percent, amendment of February 12). Vanguard Group amendment · Portfolio Management filing · Capital Management filing · Contrarius amendment · Goldman Sachs amendment.

President and Chief Executive Officer John M. Leonard reported selling 9,000 shares on November 2 under a trading plan adopted in May. His November 3 Form 4 uses code S and shows 1,138,064 direct shares and another 58,415 held indirectly through a trust. A Form 144 filed on November 2 had indicated a proposed transaction. The Form 4 records the completed sale. Chief Accounting Officer Michael P. Dube reported a separate sale of 1,864 shares on October 2. The filing describes the code S transaction as an automatic sale to cover tax withholding when restricted stock units vested. Leonard Form 4 · Leonard Form 144 · Dube Form 4.

Nasdaq’s October 30 settlement report shows 44,361,762 shares short, against 44,435,219 at October 15. Average daily volume during the reporting window fell from 6,891,382 to 4,013,427 shares. Days to cover increased from 6.45 to 11.05 as the comparison volume declined. Merlintrader calculation: the October 30 short balance equals roughly 31.61 percent of the 140,358,512 shares outstanding reported for the same date. That ratio uses issuer shares outstanding as the denominator. The Financial Industry Regulatory Authority scheduled the November 13 settlement publication for November 24. The September Form 10-Q lists the common stock on the Nasdaq Global Market. Nasdaq short-interest reporting · Publication schedule · Cover and exchange listing.

13 Legal contingencies and the evidence that will change the valuation

The September filing describes a patent infringement action in the U.S. District Court for the District of Delaware, Civil Action No. 24-791. The plaintiff seeks unspecified compensatory damages and an injunction concerning the activities it challenges. The court denied Intellia’s initial dismissal request in December 2024. A secondary report published in May 2026 states that Intellia dismissed four of its counterclaims by stipulation and that the court approved the dismissal with prejudice. The September Form 10-Q still describes the patent action and gives no details on that stipulation, so this account is not confirmed by a primary filing; readers can verify it in the report linked here. Intellia reported no material change to outstanding litigation during the September period and said it could not estimate a possible loss or range. A contested patent claim can create cost and uncertainty while the underlying allegation remains unresolved. Note 6, litigation and contingencies · December 2024 court opinion · Secondary report on the May 2026 stipulation.

The same note details a director-compensation derivative action in the Delaware Court of Chancery, Civil Action No. 2025-0543-BWD. The allegations concern compensation to directors and related fiduciary issues. Discovery followed the July 2025 answers. Intellia’s Form 10-Q for the June quarter separately said that the District of Massachusetts dismissed a securities class action, No. 1:25-cv-01353, on June 18, 2026, and that the plaintiffs did not appeal. That case is resolved, while the two actions above remain described in the September contingencies note. September legal proceedings · June discussion of the dismissed action.

The filing also lists contingent payments of up to $130 million connected with Rewrite Therapeutics, Inc. The total comprises up to $100 million upon a regulatory approval milestone and $30 million of research milestones. Intellia described the outcome and timing as uncertain and the payments as not probable at September 30. Milestone provisions can become economically important if a program succeeds, and it matters whether a prospective obligation has reached the stage at which it becomes payable. Note 6, license and other agreements.

The first valuation question is how much a successful HAE rollout changes the company’s financing options. An approval may expand qualifying access to OrbiMed capital. Cash generation depends separately on treatment starts, commercial terms and collection. Continued progress in amyloidosis can help the value of the overall portfolio, but comparative outcome and safety data still have to arrive. This creates a sequence investors can evaluate with each public milestone: regulatory decision, commercial access, operating cash use, then stronger outcome data from the second program. Each has its own upside, costs and evidence threshold. Commercial, clinical and financing risks · Regulatory timetable · Cardiomyopathy study record.

Merlintrader Health Score · $NTLA

3.05out of 5
Balance sheet and runway · 30%3.5 / 5

Quarter-end cash and securities support management’s runway into 2028. Operating use through September approached $286 million, and the $75 million funded loan brings fees, interest and collateral conditions. Capital resources.

Catalysts · 30%3.5 / 5

The FDA decision has a dated target after a positive randomized Phase 3 trial. The paired December ATTR presentations bring earlier evidence, while pivotal ATTR outcomes remain in development. Review date · Conference agenda.

Dilution · 20%2.0 / 5

The April follow-on and earlier at-the-market issuance increased the share count: 116,317,060 shares at December 31, 2025 and 140,358,512 on October 30, 2026, about 20.7 percent more (Merlintrader calculation). Remaining offering capacity and outstanding equity awards leave additional issuance possible. Shares and offering capacity.

Trading liquidity · 10%2.5 / 5

NTLA is listed on the Nasdaq Global Market. Average daily volume was about four million shares at the latest public settlement, days to cover rose above eleven and short interest equaled about 31.6 percent of shares outstanding (Merlintrader calculation). Nasdaq short interest · Listing.

Execution · 10%3.0 / 5

Intellia deployed its HAE field team and enrolled MAGNITUDE-2 above its target. Launch access and completion of the cardiac pivotal study remain important tests. Commercial and clinical update.

Assessed November 18, 2026. Merlintrader calculation: 3.5 × 30% + 3.5 × 30% + 2.0 × 20% + 2.5 × 10% + 3.0 × 10% = 3.05 out of 5.

NTLA red flags

  • Launch costs precede treatment receipts. Approval, payer coverage and cash collection have separate timelines. Commercial risks.
  • Varying clinical evidence by cohort. The long-term Phase 1 amyloidosis poster concerns a subset of hereditary polyneuropathy participants with no concurrent randomized control. Design and follow-up.
  • Liver-safety signal in the cardiomyopathy trial. Severe liver injury led to a prior hold. The upcoming conference analysis and pivotal trials address remaining questions. Clinical history.
  • Borrowing depends on specified milestones. The largest additional committed term loans depend on approval, product revenue or fundraising. Financing disclosure.

NTLA Stock FAQ: Intellia Therapeutics, Inc. Questions Answered

What is the next scheduled catalyst for Intellia stock?

December 7, 2026 is the next scheduled conference catalyst for Intellia. The cardiovascular trials forum lists two nex-z presentations on cardiac follow-up and liver-safety evidence. Both are scientific presentations, ahead of the March 2027 HAE decision target. December 7 agenda.

When is the FDA decision target for Intellia’s lonvo-z?

March 10, 2027 is the FDA target action date for lonvo-z in hereditary angioedema. Intellia announced Priority Review on September 8, 2026. The application is pending, and the eventual decision will determine the approved use if authorized. Acceptance disclosure.

How much does NTLA hold in cash and marketable securities?

At September 30, 2026, Intellia reported $614.8 million in cash, cash equivalents and marketable securities. Management expects its cash and collaboration funding to support operations at least into 2028 under its current plan. Liquidity and capital resources · Quarterly release.

What could dilute holders of NTLA common stock?

On October 30, 2026, Intellia had 140,358,512 shares outstanding. The September filing reports that Intellia can sell more shares through its at-the-market program. Stock units can add shares upon settlement and options upon exercise. Share counts and equity instruments.

When did Intellia last report financial results?

Intellia announced September-quarter financial results on November 5, 2026. It reported $7.163 million of collaboration revenue and a $127.485 million net loss for the period. Earnings Form 8-K · Quarterly statements.

What does Intellia Therapeutics develop?

In its November 5, 2026 update, Intellia described two late-stage genetic medicine candidates. Lonvo-z is under review for hereditary angioedema. Nex-z is in trials for two forms of transthyretin amyloidosis. Clinical and business update.

What did Intellia present about nex-z in November?

On November 9, 2026, Intellia presented a post hoc Phase 1 cardiac analysis at the American Heart Association Scientific Sessions. On November 18, 2026, it presented open-label Phase 1 follow-up on nex-z in hereditary polyneuropathy. The poster describes sustained reductions in circulating transthyretin and safety observations in a small group. MAGNITUDE-2 is a separate Phase 3 study. November 18 poster · Phase 3 registry.

Sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $NTLA or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, court records and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Biotechnology and pharmaceutical companies carry clinical, regulatory, commercial and financing risk, including dilution, and readers can lose capital. Readers are responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.